Diagnostic Criteria for COPD

Core Diagnostic Testing

The European Respiratory Society recommends pre-bronchodilator spirometry to rule out COPD; if FEV1/FVC ≥0.7, no further testing is needed in most cases 1, 2
Post-bronchodilator spirometry is required to confirm diagnosis when pre-bronchodilator values show FEV1/FVC <0.7 1, 2
The diagnostic threshold is post-bronchodilator FEV1/FVC <0.7, which defines persistent airflow obstruction 1, 3
Repeat spirometry on a separate occasion (within 3-6 months) is recommended if post-bronchodilator FEV1/FVC falls between 0.60-0.80 to account for biological variation 2
Post-bronchodilator FEV1 percentage predicted classifies severity: mild (≥80%), moderate (50-80%), severe (30-50%), very severe (<30%) 3

Administer bronchodilator (typically short-acting beta-agonist or anticholinergic) and repeat spirometry 15-20 minutes later 1, 4
A positive response is defined as FEV1 increase ≥200 ml AND ≥15% from baseline 4
Substantial bronchodilator response suggests possible asthma rather than COPD 4
Many COPD patients show some degree of bronchodilator response, so this does not exclude COPD diagnosis 4

The American Thoracic Society recommends the Modified Medical Research Council (mMRC) dyspnea scale to grade breathlessness from 0 (only with strenuous exercise) to 4 (too breathless to leave house) 3
The COPD Assessment Test (CAT) or clinical COPD questionnaire can quantify symptom burden 3, 5
These tools are essential for multidimensional assessment beyond spirometry alone 3, 5

Chest X-ray can exclude alternative diagnoses and identify concomitant respiratory diseases 6
Chest radiography is frequently normal in early COPD and cannot positively diagnose the disease 4, 6
CT scanning is not routinely required for initial diagnosis but can estimate emphysema degree and distribution 6

Arterial blood gas testing is mandatory for patients with severe COPD (FEV1 <50% predicted) to identify hypoxemia with or without hypercapnia 4

Prolonged expiratory phase (>5 seconds) indicates airflow limitation but does not guide severity 7
Diminished breath sounds, reduced chest expansion, hyperresonance, and visible accessory muscle use or pursed-lip breathing suggest severe obstruction 7
Central cyanosis with significant hypoxemia and signs of cor pulmonale: peripheral edema, raised jugular venous pressure, hepatic enlargement 7

Consider trial of oral corticosteroids (30 mg prednisolone daily for 2 weeks) with pre- and post-treatment spirometry for moderate-severe disease 4
Objective improvement (FEV1 increase ≥200 ml and ≥15%) occurs in 10-20% of cases 4
Actively screen for lung cancer, cardiovascular diseases, metabolic syndrome, diabetes, osteoporosis, anxiety, and depression, as these comorbidities significantly impact disease severity and prognosis 5

The European Respiratory Society recommends suspecting COPD in patients over 40 years old with chronic respiratory symptoms and significant exposure to tobacco smoke or occupational/environmental pollutants, and confirming the diagnosis with post-bronchodilator spirometry showing FEV1/FVC <0.7 8, 9, 10
Patients with COPD often present with progressive dyspnea that worsens over time, is characteristically worse with exercise, and persists throughout the day 10
Chronic cough and chronic sputum production are also common symptoms of COPD 10
Recurrent lower respiratory tract infections, particularly during winter months, can be a symptom of COPD 10
Wheezing during tidal breathing can be a sign of COPD 11

Post-bronchodilator FEV1/FVC ratio ≤0.7 confirms persistent airflow limitation that is not fully reversible 8, 9, 12, 13
The Global Initiative for Chronic Obstructive Lung Disease (GOLD) classifies COPD severity based on post-bronchodilator FEV1 percentage predicted: mild (≥80%), moderate (50-80%), severe (30-50%), and very severe (<30%) 8, 9, 13

Asthma is characterized by variable airflow limitation, marked improvement on spirometry with bronchodilators or glucocorticosteroids, and often associated with atopy and allergic conditions 9, 14
COPD is characterized by persistent airflow limitation, post-bronchodilator FEV1/FVC <0.70, and typically develops after age 40 with significant smoking history 9, 14

The modified Medical Research Council (mMRC) dyspnea scale is used to evaluate symptom severity, with grades ranging from 0 (breathless only with strenuous exercise) to 4 (too breathless to leave house or breathless when dressing) 15, 10
A history of earlier treated events is the best predictor of frequent exacerbations (≥2 per year) 10
Hospitalization for COPD exacerbation indicates poor prognosis and increased risk of death 10
Comorbidity screening should include lung cancer, cardiovascular diseases, and other conditions 9, 10

A normal physical examination is common in early COPD, but as the disease progresses, signs become apparent, and measuring respiratory rate, weight, height, and BMI in all patients is essential, as stated by the European Respiratory Society 16

Advanced disease shows nearly pathognomonic signs, and a thorough physical examination is crucial for diagnosis and assessment, according to the European Respiratory Journal 16